Sarepta Therapeutics Inc (SRPT)
128.77
+1.38
(+1.08%)
USD |
NASDAQ |
Apr 26, 16:00
128.73
-0.04
(-0.03%)
After-Hours: 20:00
Sarepta Therapeutics Cash from Financing (Quarterly): 1.943M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.943M |
September 30, 2023 | 15.40M |
June 30, 2023 | 5.861M |
March 31, 2023 | 101.80M |
December 31, 2022 | 10.75M |
September 30, 2022 | 216.43M |
June 30, 2022 | 0.339M |
March 31, 2022 | 4.99M |
December 31, 2021 | 549.25M |
September 30, 2021 | 5.902M |
June 30, 2021 | 3.526M |
March 31, 2021 | 2.893M |
December 31, 2020 | 326.94M |
September 30, 2020 | 18.79M |
June 30, 2020 | 17.58M |
March 31, 2020 | 319.02M |
December 31, 2019 | 256.97M |
September 30, 2019 | 1.733M |
June 30, 2019 | 6.292M |
March 31, 2019 | 377.56M |
December 31, 2018 | 521.28M |
September 30, 2018 | -23.96M |
June 30, 2018 | 25.35M |
March 31, 2018 | 7.471M |
December 31, 2017 | 506.81M |
Date | Value |
---|---|
September 30, 2017 | 382.24M |
June 30, 2017 | -1.174M |
March 31, 2017 | 0.206M |
December 31, 2016 | 7.287M |
September 30, 2016 | 333.71M |
June 30, 2016 | 38.17M |
March 31, 2016 | -1.037M |
December 31, 2015 | 125.58M |
September 30, 2015 | 1.576M |
June 30, 2015 | 20.25M |
March 31, 2015 | 0.406M |
December 31, 2014 | 0.024M |
September 30, 2014 | 5.407M |
June 30, 2014 | 96.03M |
March 31, 2014 | 2.69M |
December 31, 2013 | 1.965M |
September 30, 2013 | 139.01M |
June 30, 2013 | 1.721M |
March 31, 2013 | 2.971M |
December 31, 2012 | 157.26M |
September 30, 2012 | 21.38M |
June 30, 2012 | -0.021M |
March 31, 2012 | -0.02M |
December 31, 2011 | -0.02M |
September 30, 2011 | 0.011M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.339M
Minimum
Jun 2022
549.25M
Maximum
Dec 2021
98.23M
Average
10.75M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
PTC Therapeutics Inc | 620.48M |
Amgen Inc | 2.754B |
Regenxbio Inc | -11.96M |
Apellis Pharmaceuticals Inc | -3.913M |
Alnylam Pharmaceuticals Inc | 39.23M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -54.66M |
Cash from Investing (Quarterly) | -64.36M |
Free Cash Flow | -588.34M |
Free Cash Flow Per Share (Quarterly) | -0.7102 |
Free Cash Flow to Equity (Quarterly) | -74.94M |
Free Cash Flow to Firm (Quarterly) | -73.70M |
Free Cash Flow Yield | -4.94% |